(Q53433727)

English

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.

scientific article published on 15 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

8

object named as

Dong-Young Noh

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

9

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

4

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

3

object named as

Do-Youn Oh

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

2

object named as

Sae-Won Han

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

10

object named as

Tae-You Kim

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

1

object named as

Hye Jung Chang

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

author name string

Yoon Kyung Jeon

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

In Ae Park

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

Wonshick Han

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

publication date

15 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

41

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

593-599

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Nationwide cancer incidence in Korea, 2003-2005.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Estrogen receptor and breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

HER-2/neu expression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR020

21 January 2018

Identifiers

10.1093/JJCO/HYR020

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21406492

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53433727&oldid=1855152332"